Refractory Solid Tumor Clinical Trial
Official title:
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03690869 -
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03443622 -
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06375564 -
Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
|
Phase 1 | |
| Active, not recruiting |
NCT01558453 -
Oxaliplatin for Children With Solid Tumors
|
Phase 2 | |
| Terminated |
NCT02164097 -
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05963386 -
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
|
Phase 1 | |
| Completed |
NCT00110357 -
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
|
Phase 1 |